NEW YORK, April 9, 2019 /PRNewswire/ -- Global X ETFs, the New York-based provider of exchange-traded funds, announced today the launch of the 13th fund in its Thematic Growth suite, the Global X Genomics & Biotechnology ETF (Nasdaq: GNOM). Designed to track the Solactive Genomics Index, the fund holds a basket of companies that potentially stand to benefit from advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.
GNOM's launch comes at a time when the DNA sequencing market is experiencing significant growth, with estimates expecting the market to grow from $6.2 billion in 2017 to $25.5 billion by 2025 – representing a compound annual growth rate of 19%.i As a result of significant technological advances in the field, it's estimated that anyone with $100 can now sequence their DNA, down from the $100 million it was estimated to cost in 2001.ii
"The wide-ranging and transformative health benefits from advancements in genomic technologies are astounding," said Michael Hoffmann, research analyst at Global X. "We're eager to see how investors engage with GNOM as a tool for accessing this disruptive theme."
Breakthroughs in genomic science can present new treatments to help patients recover from what were once believed to be incurable afflictions. Scientists have identified more than 50,000 genetic diseases caused by single-gene mutations, many of which are likely to be treated through genomic approaches, including several methods that have already begun to receive FDA approval.iii
ABOUT GLOBAL X
Seeking to provide access to high-quality and cost-efficient investment solutions, Global X is a New York-based sponsor of exchange-traded funds (ETFs). Founded in 2008, we are distinguished by our thematic growth, income, core, international access, commodities, alpha, and risk management suites of ETFs and have more than 60 funds available across U.S. and foreign exchanges. Global X is recognized as a leader in providing intelligent investment solutions for our clients.
Investing involves risk, including the possible loss of principal. The investable universe of companies in which GNOM may invest may be limited. The Fund invests in securities of companies engaged in Genomics, Healthcare and Biotechnology sectors. These sectors can be affected by government regulations, rapid product obsolescence, intense industry competition and loss or impairment of patents or intellectual property rights. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles or from social, economic or political instability in other nations. GNOM is non-diversified.
Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns.
Carefully consider the funds' investment objectives, risk factors, charges, and expenses before investing. This and additional information can be found in the funds' summary or full prospectus, which may be obtained by calling 1-888-GX-FUND-1 (1.888.493.8631), or by visiting globalxfunds.com. Please read the prospectus carefully before investing.
Global X Management Company LLC serves as an advisor to Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO), which is not affiliated with Global X Management Company LLC. Global X Funds are not sponsored, endorsed, issued, sold or promoted by Solactive AG, nor does Solactive AG make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO nor Global X is affiliated with Solactive AG.
i Allied Market Research, "DNA Sequencing Market: Opportunities and Forecasts, 2018-2025," Dec 2018. ii Elysium Health, "The Non-Scientist's Guide to Genetic Testing," May 22, 2018. iii WIRED, "Gene Editing is Trickier Than Expected—but Fixes Are in Sight," Feb 28, 2019.